Daily English Article — May 22, 2026

Health authorities in Philadelphia have shut down a dental clinic called Smiles at Rittenhouse Square after discovering serious sanitation violations. The Pennsylvania Department of State suspended the license of Dr. Kirti Chopra, the clinic's practicing dentist, citing unsanitary conditions that posed an immediate threat to public health. The clinic, located in Center City Philadelphia, is now closed and will remain so until all safety concerns are fully resolved and the dentist's license is reinstated.

Officials are urging former patients who visited the clinic between April 2025 and May 2026 to get tested for Hepatitis B, Hepatitis C, and HIV. The Philadelphia Department of Public Health is working with the clinic to compile a patient list, and affected individuals will be notified by mail. They will also receive a letter to present to their own healthcare provider explaining the situation and recommending appropriate testing steps.

James Garrow, the communications director for the Philadelphia Department of Public Health, confirmed the office was shut down on May 15 after officials verified the clinic was not following proper sanitization and safety procedures. He noted that any time sharp instruments are used in the mouth, there is potential for bloodborne pathogens to be transferred. Despite this risk, there are currently no known infections linked to the practice, and health officials believe the overall risk to patients remains relatively low.

State investigation documents revealed that Dr. Chopra admitted to reusing single-use items, including anesthesia vials, which put patients at serious risk of contracting hepatitis, HIV, and other viral, bacterial, or fungal infections. Dental handpieces were also being reused without proper sanitization between patients. Dr. Chopra, through her attorney, issued a statement saying she is cooperating with public health authorities and will not comment further while a regulatory proceeding is ongoing.

Patients who learned of the potential exposure reacted with shock and anger. Kathleen Poliski, who had been at the clinic just two weeks prior for a routine teeth cleaning, said she was speechless and criticized the dentist for failing to notify patients directly. Many learned of the situation through social media rather than official channels. The city health department has stated that the clinic will not be permitted to reopen until it is fully satisfied that all unsafe practices have been corrected.

At this year's Google I/O keynote, Google DeepMind CEO Demis Hassabis made a striking declaration: that the company hopes to one day solve all disease by reimagining the drug discovery process. The statement drew attention for its sweeping ambition. What Hassabis was actually presenting was Gemini for Science, a suite of experimental AI tools intended to help researchers accelerate exploration and discovery in the life sciences and related fields.

The author of The Verge's health-focused newsletter Optimizer argues that while bold claims from tech leaders are common, Hassabis' statement deserves important context. Good science communication, she writes, should be accessible to the general public without inadvertently spreading misinformation. Researchers in the audience likely understood the claim as a reference to AI's growing ability to shorten the timelines of medical discoveries, but to an average listener it may have sounded like a promise to cure every illness.

AI has in fact played a significant role in medical research for decades. Machine learning underpins the algorithms used in consumer health wearables, and generative AI represents a newer but highly promising advancement in the field. A meta-review cited in the article found that AI contributed meaningfully to compressing the development timeline for COVID-19 vaccines — a benefit that reached people globally. However, the same review highlighted persistent challenges including algorithmic bias, data privacy concerns, and unequal access to these technologies worldwide.

Hassabis specifically highlighted two of Google's flagship scientific AI projects: AlphaFold and AlphaGenome. AlphaFold helps researchers understand complex protein structures, which is critical because proteins are involved in virtually every biological process in the human body. A deeper understanding of proteins — or the ability to design entirely new synthetic ones — could unlock transformative treatments for diseases like cancer. Recently, scientists identified 1,700 previously unknown proteins that may hold therapeutic potential.

The article ultimately makes the case that the real promise of AI in medicine lies not in sweeping proclamations but in incremental, verifiable progress. Reducing vaccine development timelines, improving our understanding of molecular biology, and enabling faster data analysis are genuine achievements. However, the gap between a powerful AI tool and an actual cure for disease remains vast and involves rigorous clinical trials, regulatory approval, and ethical scrutiny. Technology leaders, the author implies, have a responsibility to communicate these distinctions clearly.